NCT03232086 (RECAP) is a NA clinical trial of Clean Air in Exposure to Pollution, sponsored by Environmental Protection Agency (EPA).

Who is sponsoring NCT03232086?

NCT03232086 is sponsored by Environmental Protection Agency (EPA).

What drugs are being tested in NCT03232086?

Interventions in NCT03232086: Clean Air, PM2.5.

What condition does NCT03232086 study?

NCT03232086 studies Exposure to Pollution.

Is NCT03232086 still recruiting?

NCT03232086 is currently completed. Last updated 5 September 2021.

Last reviewed 2021-09-05 · How we verify

NCT03232086: RECAP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Responses to Exposure to Low Levels of Concentrated Ambient Particles in Healthy Young Adults

Completed NA Last updated 5 September 2021

What this trial tests

NA trial testing Clean Air in Exposure to Pollution in 20 participants. Completed in 30 July 2020.

Timeline

16 January 2017

Primary endpoint
20 January 2019

30 July 2020

Quick facts

Lead sponsor	Environmental Protection Agency (EPA)
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	20
Start date	16 January 2017
Primary completion	20 January 2019
Estimated completion	30 July 2020
Sites	1 location across United States

Drugs / interventions tested

Clean Air
PM2.5

Conditions studied

Exposure to Pollution — all drugs for Exposure to Pollution →

Sponsor

Environmental Protection Agency (EPA)

Who can join

Adults 18 to 35, any sex, with Exposure to Pollution. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose: To determine whether exposure to levels of fine particles that are close to the current standard will cause cardiovascular changes in healthy individuals.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Low levels of fine particulate matter increase vascular damage and reduce pulmonary function in young healthy adults.
Wyatt LH, Devlin RB, Rappold AG, Case MW, et al · · 2020 · cited 25× · PMID 33198760 · DOI 10.1186/s12989-020-00389-5

Verify or expand the search:

Other trials of Clean Air

Trials testing the same drug.

NCT05794087 — The Role of Macrophage Activation in Lung Injury Following Ozone Exposure · NA · recruiting
NCT04315740 — Acute Health Effects Due to Ultrafine Particles From Candles and Cooking · NA · completed

Other recruiting trials for Exposure to Pollution

Currently open trials in the same condition.

NCT03615742 — Diesel Exhaust Induces Glucocorticoid Resistance · Phase 4 · recruiting

Other Environmental Protection Agency (EPA) trials

Trials by the same sponsor.

NCT05944770 — ASPIRE Health Tulare County · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03232086 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Environmental Protection Agency (EPA)
Last refreshed: 5 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03232086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing